[HTML][HTML] COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
MC Garassino, JG Whisenant, LC Huang… - The Lancet …, 2020 - thelancet.com
Background Early reports on patients with cancer and COVID-19 have suggested a high
mortality rate compared with the general population. Patients with thoracic malignancies are …
mortality rate compared with the general population. Patients with thoracic malignancies are …
Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase− positive non–small cell lung cancer: a randomized clinical trial
…, I Cicin, Y Cheng, Y Liu, Y Fan, JG Whisenant… - JAMA …, 2021 - jamanetwork.com
Importance Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK),
has shown systemic and central nervous system efficacy for patients withALK-positive non–…
has shown systemic and central nervous system efficacy for patients withALK-positive non–…
Amide proton transfer imaging of the breast at 3 T: establishing reproducibility and possible feasibility assessing chemotherapy response
Chemical exchange saturation transfer imaging can generate contrast that is sensitive to
amide protons associated with proteins and peptides (termed amide proton transfer, APT). In …
amide protons associated with proteins and peptides (termed amide proton transfer, APT). In …
Ensartinib (X-396) in ALK-positive non–small cell lung cancer: results from a first-in-human phase I/II, multicenter study
…, SN Waqar, BJ Gitlitz, RE Sanborn, JG Whisenant… - Clinical Cancer …, 2018 - AACR
Purpose: Evaluate safety and determine the recommended phase II dose (RP2D) of ensartinib
(X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), and …
(X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), and …
[HTML][HTML] Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer
Introduction Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in
patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of …
patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of …
COVID-19 and cancer: a review of the registry-based pandemic response
Importance The COVID-19 pandemic has had consequences for patients with cancer worldwide
and has been associated with delays in diagnosis, interruption of treatment and follow-…
and has been associated with delays in diagnosis, interruption of treatment and follow-…
[HTML][HTML] Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation
SL Barnes, JG Whisenant, ME Loveless, TE Yankeelov - Pharmaceutics, 2012 - mdpi.com
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) consists of the
continuous acquisition of images before, during, and after the injection of a contrast agent. DCE-…
continuous acquisition of images before, during, and after the injection of a contrast agent. DCE-…
[PDF][PDF] TERAVOLT: thoracic cancers international COVID-19 collaboration
JG Whisenant, A Trama, V Torri, A De Toma, G Viscardi… - Cancer Cell, 2020 - cell.com
Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown
an increased risk of mortality compared to the general population. Furthermore, patients …
an increased risk of mortality compared to the general population. Furthermore, patients …
Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.
LBA111 Background: Early reports on cancer patients infected with COVID-19 have
suggested a high mortality rate compared to the general population. Patients with thoracic …
suggested a high mortality rate compared to the general population. Patients with thoracic …
Mean apparent diffusion coefficient is a sufficient conventional diffusion-weighted MRI metric to improve breast MRI diagnostic performance: results from the ECOG …
Background The Eastern Cooperative Oncology Group and American College of Radiology
Imaging Network Cancer Research Group A6702 multicenter trial helped confirm the …
Imaging Network Cancer Research Group A6702 multicenter trial helped confirm the …